Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Low dose ARA-C (LDAC)
DRUG
2 trials
Sponsors
Pfizer
Conditions
Acute Myeloid Leukemia
Phase 1
A Study Of PF-04449913 In Japanese Patients With Select Hematologic Malignancies
Completed
NCT02038777
Pfizer
Acute Myeloid Leukemia
Start: 2014-03-25
End: 2023-12-28
Updated: 2025-02-26
Phase 2
A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Completed
NCT01546038
Pfizer
Acute Myeloid Leukemia
Start: 2012-06-27
End: 2019-03-04
Updated: 2020-03-03
Related Papers
Glasdegib with intensive/nonintensive chemotherapy in Japanese patients with untreated acute myeloid leukemia or high‐risk myelodysplastic syndromes
Cancer Science
2024-02-07
3 citations
Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial
Annals of Hematology
2021-03-19
52 citations
An evaluation of overall survival in patients with newly diagnosed acute myeloid leukemia and the relationship with glasdegib treatment and exposure.
2020-09-03
6 citations
Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy.
2020-07-14
27 citations
Glasdegib (GLAS) plus low-dose cytarabine (LDAC) in AML or MDS: BRIGHT AML 1003 final report and four-year overall survival (OS) follow-up.
Journal of Clinical Oncology
2020-05-20
10 citations
Effect of early blood counts on overall survival (OS) following glasdegib + LDAC in newly diagnosed AML: BRIGHT AML 1003 post hoc analysis.
Journal of Clinical Oncology
2020-05-20
1 citations
Clinical Benefit of Glasdegib in Combination with Azacitidine or Low-Dose Cytarabine in Patients with Acute Myeloid Leukemia
Blood
2019-11-13
12 citations
Quality-Adjusted Survival for Low-Dose Cytarabine (LDAC) Versus Glasdegib+LDAC Among Newly Diagnosed Acute Myeloid Leukemia Patients Who Are Not Candidates for Intensive Chemotherapy: A Q-TWiST Analysis
Blood
2019-11-13
2 citations
Abstract LB-009: Biomarkers correlating with overall survival (OS) and response to glasdegib and intensive or nonintensive chemotherapy in patients with acute myeloid leukemia (AML)
Cancer Research
2019-07-01
1 citations
Abstract LB-009: Biomarkers correlating with overall survival (OS) and response to glasdegib and intensive or nonintensive chemotherapy in patients with acute myeloid leukemia (AML)
Clinical Research (Excluding Clinical Trials)
2019-07-01
PF272 GLASDEGIB WITH LDAC IN NEWLY DIAGNOSED PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) UNSUITABLE FOR INTENSIVE CHEMOTHERAPY: EFFECTS ON TRANSFUSIONS AND MARROW RECOVERY VS LDAC ALONE
HemaSphere
2019-06-01
2 citations
PF292 LOW‐DOSE CYTARABINE WITH OR WITHOUT GLASDEGIB IN NEWLY DIAGNOSED PATIENTS WITH ACUTE MYELOID LEUKEMIA: LONG‐TERM ANALYSIS OF A PHASE 2 RANDOMIZED TRIAL
HemaSphere
2019-06-01
1 citations
PS1030 COMPLETE REMISSION WITH INCOMPLETE BLOOD COUNT RECOVERY IS A STRONG PREDICTOR OF NON-RELAPSE MORTALITY IN ACUTE MYELOID LEUKEMIA PATIENTS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION
HemaSphere
2019-06-01
Low-dose cytarabine with or without glasdegib in newly diagnosed patients with acute myeloid leukemia: Long-term analysis of a phase 2 randomized trial.
Journal of Clinical Oncology
2019-05-20
6 citations
New FDA Approved Therapies for AML & Impact on the Older Population
Oncology Times
2019-03-14
Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome
Leukemia
2018-12-16
473 citations
Glasdegib in Addition to Intensive or Non-Intensive Chemotherapy in Patients with Acute Myeloid Leukemia: Safety Analysis of Glasdegib 'On Target' Adverse Events
Blood
2018-11-29
5 citations
Biomarkers of Overall Survival and Response to Glasdegib and Intensive or Non-Intensive Chemotherapy in Patients with Acute Myeloid Leukemia
Blood
2018-11-29
4 citations
Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high‐risk MDS: Phase 2 study results
American Journal of Hematology
2018-08-07
113 citations
Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS
Clinical Cancer Research
2018-02-20
105 citations
1 more papers not shown